In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- Experts weigh in on liability over AI use in healthcare (Healio)
- Ascension’s Outpatient Surgery Volume Rose Nearly 400% After AMSURG Buy (ASC News)
- CMS Finalizes Reassignment of Gastric Alimetry® Test to Higher Payment Level, Increasing Medicare Hospital Outpatient Payment by Approximately 144% (Globe Newswire )
- MedInTech Secures $25.7 Million for AI Robotics Expansion (DistilINFO)
- AI-assisted colonoscopy and disease-specific imaging show benefits in ulcerative colitis (Hospital Healthcare Europe)
- The race to understand why young people are dying from colon cancer (Scientific American)
- What the Robot Still Can’t Do (NEJM)
- Geneoscopy Resolves Patent and False Advertising Litigation with Exact Sciences Following a Series of Victories at the Patent Trial and Appeal Board (PR Newswire)
